Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT ID: NCT04401748

Last Updated: 2025-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

531 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-10

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death from the disease itself. Symptoms of MDS include fatigue, shortness of breath, unusual paleness due to anemia (low red blood cell count), easy or unusual bruising, and red spots just beneath the skin caused by bleeding. The purpose of this study is to see how safe and effective venetoclax and azacitidine (AZA) combination are when compared to AZA and a placebo (contains no medicine), in participants with newly diagnosed higher-risk MDS.

Venetoclax is an investigational drug being developed for the treatment of MDS. The study consists of two treatment arms - In one arm, participants will receive venetoclax and AZA. In another arm, participants will receive AZA and placebo. Adult participants with newly diagnosed higher-risk MDS will be enrolled. Around 500 participants will be enrolled in approximately 220 sites worldwide.

Participants in one arm will receive oral doses of venetoclax tablet and intravenous (infusion in the vein) or subcutaneous (given under the skin) AZA solution. Participants in another arm will receive oral doses of placebo tablet and intravenous or subcutaneous AZA solution.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndrome (MDS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: Venetoclax + Azacitidine (AZA)

Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.

Group Type EXPERIMENTAL

Venetoclax

Intervention Type DRUG

Tablet: Oral

Azacitidine

Intervention Type DRUG

Subcutaneous (SC) or Intravenous (IV) injection

Arm 2: Placebo + Azacitidine

Participants will receive placebo once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.

Group Type ACTIVE_COMPARATOR

Azacitidine

Intervention Type DRUG

Subcutaneous (SC) or Intravenous (IV) injection

Placebo

Intervention Type DRUG

Tablet; Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venetoclax

Tablet: Oral

Intervention Type DRUG

Azacitidine

Subcutaneous (SC) or Intravenous (IV) injection

Intervention Type DRUG

Placebo

Tablet; Oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABT-199 GDC-0199 Venclexta AZA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with a diagnosis of Myelodysplastic Syndrome (MDS) according to the 2016 World Health Organization (WHO) classification wtih presence of \< 20% bone marrow blasts per marrow biopsy/aspirate at screening.
* Participants must meet the following disease activity criteria:

* Overall Revised International Prognostic Scoring System (IPSS-R) score \> 3 (intermediate, high or very high).
* Eastern Cooperative Oncology Group (ECOG) performance status of \<= 2.
* Hematopoietic stem cell transplant (HSCT) eligible with no pre-arranged HSCT at the time of Study Day 1, or HSCT ineligible without plan for HSCT at the time of Study Day 1.

Exclusion Criteria

* Prior therapy for MDS with any hypomethylating agent, chemotherapy, or allogenic stem cell transplantation.
* Prior diagnosis of therapy-related MDS (t-MDS), MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genentech, Inc.

INDUSTRY

Sponsor Role collaborator

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Duplicate_Providence Medical Foundation /ID# 222633

Fullerton, California, United States

Site Status

University of California, Los Angeles /ID# 221760

Los Angeles, California, United States

Site Status

Torrance Memorial Physician Network Cancer Care /ID# 222702

Torrance, California, United States

Site Status

PIH Health Whittier Hospital /ID# 222647

Whittier, California, United States

Site Status

Rocky Mountain Cancer Centers - Boulder /ID# 223723

Boulder, Colorado, United States

Site Status

Yale University School of Medicine /ID# 222764

New Haven, Connecticut, United States

Site Status

Helen F. Graham Cancer Center & Research Institute /ID# 223731

Newark, Delaware, United States

Site Status

Florida Cancer Specialists - Fort Myers /ID# 221319

Fort Myers, Florida, United States

Site Status

Memorial Healthcare System /ID# 222703

Hollywood, Florida, United States

Site Status

Florida Cancer Specialists - North /ID# 221318

St. Petersburg, Florida, United States

Site Status

Florida Cancer Specialists - Panhandle /ID# 221315

Tallahassee, Florida, United States

Site Status

Florida Cancer Specialists - East /ID# 221317

West Palm Beach, Florida, United States

Site Status

St. Luke's Mountain State Tumor Institute /ID# 220838

Boise, Idaho, United States

Site Status

Northwestern University Feinberg School of Medicine /ID# 220843

Chicago, Illinois, United States

Site Status

Duplicate_Rush University Medical Center /ID# 221007

Chicago, Illinois, United States

Site Status

Ingalls Memorial Hosp /ID# 220844

Harvey, Illinois, United States

Site Status

Illinois Cancer Care, PC /ID# 220840

Peoria, Illinois, United States

Site Status

Duplicate_Parkview Cancer Institute /ID# 223620

Fort Wayne, Indiana, United States

Site Status

Cancer Center of Kansas /ID# 222648

Wichita, Kansas, United States

Site Status

Hematology/Oncology Clinic /ID# 224257

Baton Rouge, Louisiana, United States

Site Status

Pontchartrain Cancer Center - Covington /ID# 221005

Covington, Louisiana, United States

Site Status

Maryland Oncology Hematology /ID# 223776

Columbia, Maryland, United States

Site Status

Massachusetts General Hospital /ID# 225068

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical Center /ID# 225069

Boston, Massachusetts, United States

Site Status

Dana-Farber Cancer Institute /ID# 219162

Boston, Massachusetts, United States

Site Status

VA Ann Arbor Healthcare System /ID# 221365

Ann Arbor, Michigan, United States

Site Status

Cancer & Hematology Centers /ID# 220848

Grand Rapids, Michigan, United States

Site Status

Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 221321

Saint Louis Park, Minnesota, United States

Site Status

MidAmerica Division, Inc. /ID# 221895

Kansas City, Missouri, United States

Site Status

Comprehensive Cancer Centers of Nevada - Horizon Ridge /ID# 222635

Henderson, Nevada, United States

Site Status

Titan Health Partners LLC, d/b/a Astera Cancer Care /ID# 221003

East Brunswick, New Jersey, United States

Site Status

The Valley Hospital /ID# 232337

Paramus, New Jersey, United States

Site Status

New York Oncology Hematology - Albany Cancer Center /ID# 223778

Albany, New York, United States

Site Status

University at Buffalo /ID# 221206

Buffalo, New York, United States

Site Status

Weill Cornell Medical College /ID# 222898

New York, New York, United States

Site Status

Stony Brook University Hospital /ID# 224450

Stony Brook, New York, United States

Site Status

Novant Health Presbyterian Medical Center /ID# 222561

Charlotte, North Carolina, United States

Site Status

Novant Health Forsyth Medical Center /ID# 221004

Winston-Salem, North Carolina, United States

Site Status

Oncology Hematology Care, Inc. /ID# 223724

Cincinnati, Ohio, United States

Site Status

Bend Memorial Clinic /ID# 220999

Bend, Oregon, United States

Site Status

Willamette Valley Cancer Institute and Research Center /ID# 223733

Eugene, Oregon, United States

Site Status

UPMC Hillman Cancer Ctr /ID# 223201

Pittsburgh, Pennsylvania, United States

Site Status

Avera Cancer Institute /ID# 243461

Sioux Falls, South Dakota, United States

Site Status

Tennessee Oncology - Chattanooga / McCallie /ID# 221311

Chattanooga, Tennessee, United States

Site Status

Tennessee Oncology-Nashville Centennial /ID# 220854

Nashville, Tennessee, United States

Site Status

Texas Oncology - Austin Midtown /ID# 223729

Austin, Texas, United States

Site Status

Duplicate_Texas Oncology - Medical City Dallas /ID# 223725

Dallas, Texas, United States

Site Status

Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 223727

Dallas, Texas, United States

Site Status

Texas Oncology - Forth Worth /ID# 223777

Fort Worth, Texas, United States

Site Status

MD Anderson Cancer Center at Texas Medical Center /ID# 219163

Houston, Texas, United States

Site Status

Texas Oncology - San Antonio Medical Center - Research Drive /ID# 223728

San Antonio, Texas, United States

Site Status

Baylor Scott & White Medical Center- Temple /ID# 221332

Temple, Texas, United States

Site Status

Texas Oncology - Northeast Texas /ID# 223734

Tyler, Texas, United States

Site Status

Utah Cancer Specialists Salt Lake Clinic /ID# 219160

Salt Lake City, Utah, United States

Site Status

Virginia Cancer Specialists - Gainesville /ID# 223726

Gainesville, Virginia, United States

Site Status

Virginia Commonwealth University Medical Center Main Hospital /ID# 221590

Richmond, Virginia, United States

Site Status

Virginia Cancer Institute at Reynolds Crossing /ID# 221002

Richmond, Virginia, United States

Site Status

VA Puget Sound Health Care System /ID# 221358

Seattle, Washington, United States

Site Status

Duplicate_Blacktown Hospital /ID# 234079

Blacktown, New South Wales, Australia

Site Status

St George Hospital /ID# 221810

Kogarah, New South Wales, Australia

Site Status

Port Macquarie Base Hospital /ID# 234078

Port Macquarie, New South Wales, Australia

Site Status

Gold coast University Hospital /ID# 222606

Southport, Queensland, Australia

Site Status

Royal Adelaide Hospital /ID# 221805

Adelaide, South Australia, Australia

Site Status

St Vincent's Hospital Melbourne /ID# 221809

Fitzroy Melbourne, Victoria, Australia

Site Status

Austin Health /ID# 221807

Heidelberg, Victoria, Australia

Site Status

Ordensklinikum Linz GmbH Elisabethinen /ID# 221387

Linz, Upper Austria, Austria

Site Status

Klinikum Wels-Grieskirchen GmbH /ID# 221386

Wels, Upper Austria, Austria

Site Status

Medizinische Universitaet Wien /ID# 221446

Vienna, Vienna, Austria

Site Status

Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221092

Salzburg, , Austria

Site Status

Hanusch Krankenhaus /ID# 221093

Vienna, , Austria

Site Status

ZAS Middelheim /ID# 218907

Antwerp, Antwerpen, Belgium

Site Status

Cliniques Universitaires UCL Saint-Luc /ID# 219066

Brussels, Brussels Capital, Belgium

Site Status

Hospital La Louviere Site Jolimont - Helora /ID# 218921

La Louvière, Hainaut, Belgium

Site Status

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 219064

Yvoir, Namur, Belgium

Site Status

UZ Gent /ID# 218767

Ghent, Oost-Vlaanderen, Belgium

Site Status

Universitair Ziekenhuis Leuven /ID# 218905

Leuven, Vlaams-Brabant, Belgium

Site Status

AZ Sint-Jan Brugge /ID# 218212

Bruges, West-Vlaanderen, Belgium

Site Status

Hospital Universitario Walter Cantidio /ID# 223434

Fortaleza, Ceará, Brazil

Site Status

Hospital Erasto Gaertner /ID# 221341

Curitiba, Puerto Rico, Brazil

Site Status

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 221370

São Paulo, São Paulo, Brazil

Site Status

Hospital Universitário Pedro Ernesto /ID# 223080

Rio de Janeiro, , Brazil

Site Status

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 221339

São Paulo, , Brazil

Site Status

BC Cancer - Surrey /ID# 219098

Surrey, British Columbia, Canada

Site Status

Ottawa Hospital Research Institute /ID# 219105

Ottawa, Ontario, Canada

Site Status

Sunnybrook Health Sciences Centre /ID# 219103

Toronto, Ontario, Canada

Site Status

McGill University Health Centre - Glen Site /ID# 222519

Montreal, Quebec, Canada

Site Status

CIUSSS du Nord-de-l'ile-de-Montréal_Hopital du Sacré-Coeur de Montréal /ID# 218973

Montreal, Quebec, Canada

Site Status

CHUQ- Hôpital de l'Enfant-Jesus /ID# 221200

Québec, Quebec, Canada

Site Status

Peking University International Hospital /ID# 222987

Beijing, Beijing Municipality, China

Site Status

Lanzhou University Second Hospital /ID# 225980

Lanzhou, Gansu, China

Site Status

Guangdong Provincial People's Hospital /ID# 221442

Guangzhou, Guangdong, China

Site Status

Zhujiang Hospital of Southern Medical University /ID# 222071

Guangzhou, Guangdong, China

Site Status

Nanfang Hospital of Southern Medical University /ID# 224566

Guangzhou, Guangdong, China

Site Status

The Second Hospital of Hebei Medical University /ID# 222919

Shijiazhuang, Hebei, China

Site Status

People's Hospital of Henan Province /ID# 225790

Zhengzhou, Henan, China

Site Status

Henan Cancer Hospital /ID# 221447

Zhengzhou, Henan, China

Site Status

Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 221475

Wuhan, Hubei, China

Site Status

Tongji Hospital Tongji Medical College of HUST /ID# 221474

Wuhan, Hubei, China

Site Status

Zhongda Hospital Southeast University /ID# 221849

Nanjing, Jiangsu, China

Site Status

Jiangsu Province Hospital /ID# 221342

Nanjing, Jiangsu, China

Site Status

The First Affiliated Hospital of Soochow University /ID# 221640

Suzhou, Jiangsu, China

Site Status

The First Affiliated Hospital of Nanchang University /ID# 225983

Nanchang, Jiangxi, China

Site Status

Shengjing Hospital of China Medical University /ID# 222945

Shenyang, Liaoning, China

Site Status

Shaanxi Provincial People'S Hospital /ID# 225728

Xi'an, Shaanxi, China

Site Status

Shanghai Sixth People's Hospital /ID# 221546

Shanghai, Shanghai Municipality, China

Site Status

West China Hospital, Sichuan University /ID# 221601

Chengdu, Sichuan, China

Site Status

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 221567

Tianjin, Tianjin Municipality, China

Site Status

Tianjin Medical University General Hospital /ID# 226810

Tianjin, Tianjin Municipality, China

Site Status

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 221494

Hangzhou, Zhejiang, China

Site Status

Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 225982

Hangzhou, Zhejiang, China

Site Status

The Fourth Affiliated Hospital Zhejiang University School of Medicine /ID# 225918

Yiwu, Zhejiang, China

Site Status

Fakultní Nemocnice Brno - Jihlavská /ID# 221351

Brno, Brno-mesto, Czechia

Site Status

Fakultní nemocnice Hradec Králové - Sokolská /ID# 221163

Hradec Králové, Hradec Kralove, Czechia

Site Status

Fakultni Nemocnice Ostrava /ID# 219143

Ostrava, Ostrava-mesto, Czechia

Site Status

Fakultní Nemocnice Plzeň-Lochotín /ID# 221162

Pilsen, Plzen-jih, Czechia

Site Status

Všeobecná Fakultní Nemocnice v Praze /ID# 221229

Prague, Praha 17, Czechia

Site Status

Ustav hematologie a krevni transfuze /ID# 221350

Prague, , Czechia

Site Status

Chu de Nice-Hopital L'Archet Ii /Id# 220992

Nice, Alpes-Maritimes, France

Site Status

Centre Hospitalier Universitaire de Bordeaux /ID# 220989

Pessac, Gironde, France

Site Status

CHU Grenoble - Hopital Michallon /ID# 220988

La Tronche, Isere, France

Site Status

CHRU Lille - Hopital Claude Huriez /ID# 220991

Lille, Nord, France

Site Status

Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 222074

Nantes, Pays de la Loire Region, France

Site Status

Hopital de la Conception /ID# 224882

Marseille, Provence-Alpes-Côte d'Azur Region, France

Site Status

Centre Henri Becquerel /ID# 220986

Rouen, Seine-Maritime, France

Site Status

CH Henri Duffaut /ID# 225185

Avignon, Vaucluse, France

Site Status

Hôpital Saint-Louis /ID# 222075

Paris, , France

Site Status

Universitatsklinikum Mannheim /ID# 221172

Mannheim, Baden-Wurttemberg, Germany

Site Status

Stauferklinikum Schwaebisch Gmuend /ID# 224917

Mutlangen, Baden-Wurttemberg, Germany

Site Status

Klinikum rechts der Isar /ID# 221170

Munich, Bavaria, Germany

Site Status

Medizinische Hochschule Hannover /ID# 221173

Hanover, Lower Saxony, Germany

Site Status

Universitaetsklinikum Koeln /ID# 234219

Cologne, North Rhine-Westphalia, Germany

Site Status

Universitaetsklinikum Duesseldorf /ID# 221169

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

Universitaetsklinikum Leipzig /ID# 221168

Leipzig, Saxony, Germany

Site Status

Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 221189

Berlin, , Germany

Site Status

Fejér Vármegyei Szent György Egyetemi Oktató Kórház /ID# 222953

Székesfehérvár, Fejér, Hungary

Site Status

Duplicate_Debreceni Egyetem Klinikai Kozpont /ID# 221702

Debrecen, Hajdú-Bihar, Hungary

Site Status

Duplicate_Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 221703

Kaposvár, Somogy County, Hungary

Site Status

Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 221704

Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

Site Status

Szegedi Tudományegyetem /ID# 221705

Szeged, , Hungary

Site Status

Shaare Zedek Medical Center /ID# 233181

Jerusalem, Jerusalem, Israel

Site Status

Hadassah Medical Center-Hebrew University /ID# 222006

Jerusalem, Jerusalem, Israel

Site Status

The Chaim Sheba Medical Center /ID# 221110

Ramat Gan, Tel Aviv, Israel

Site Status

Tel Aviv Sourasky Medical Center /ID# 221896

Tel Aviv, Tel Aviv, Israel

Site Status

Rambam Health Care Campus /ID# 221083

Haifa, , Israel

Site Status

Rabin Medical Center /ID# 221184

Petah Tikva, , Israel

Site Status

IRCCS Istituto Clinico Humanitas /ID# 220815

Rozzano, Lombardy, Italy

Site Status

Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 220816

Naples, Napoli, Italy

Site Status

Duplicate_Azienda Ospedaliero-Universitaria Sant'Andrea /ID# 220819

Rome, Roma, Italy

Site Status

IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 220810

Bologna, , Italy

Site Status

Grande Ospedale Metropolitano Bianchi - Melacrino - Morelli P.O. Riuniti /ID# 220818

Reggio Calabria, , Italy

Site Status

Nagoya University Hospital /ID# 221566

Nagoya, Aichi-ken, Japan

Site Status

University of Fukui Hospital /ID# 221568

Yoshida-gun, Fukui, Japan

Site Status

Kyushu University Hospital /ID# 223473

Fukuoka, Fukuoka, Japan

Site Status

Fukushima Medical University Hospital /ID# 222015

Fukushima, Fukushima, Japan

Site Status

Chugoku Central Hospital /ID# 222955

Fukuyama, Hiroshima, Japan

Site Status

Sapporo Hokuyu Hospital /ID# 222133

Sapporo, Hokkaido, Japan

Site Status

Aiiku Hospital /ID# 222351

Sapporo, Hokkaido, Japan

Site Status

Kobe City Medical Center General Hospital /ID# 221977

Kobe, Hyōgo, Japan

Site Status

NHO Mito Medical Center /ID# 222278

Higashiibaraki-gun, Ibaraki, Japan

Site Status

Tohoku University Hospital /ID# 221976

Sendai, Miyagi, Japan

Site Status

Okayama Medical Center /ID# 222310

Okayama, Okayama-ken, Japan

Site Status

Kindai University Hospital /ID# 222284

Osakasayama-shi, Osaka, Japan

Site Status

Saitama Medical Center /ID# 222016

Kawagoe, Saitama, Japan

Site Status

NTT Medical Center Tokyo /ID# 222365

Shinagawa-ku, Tokyo, Japan

Site Status

Yamagata University Hospital /ID# 221574

Yamagata, Yamagata, Japan

Site Status

Nagasaki University Hospital /ID# 222241

Nagasaki, , Japan

Site Status

Maastricht Universitair Medisch Centrum /ID# 221630

Maastricht, Limburg, Netherlands

Site Status

Maxima Medisch Centrum /ID# 223010

Eindhoven, North Brabant, Netherlands

Site Status

Medisch Spectrum Twente /ID# 223012

Enschede, Overijssel, Netherlands

Site Status

Isala /ID# 223011

Zwolle, Overijssel, Netherlands

Site Status

Erasmus Medisch Centrum /ID# 218937

Rotterdam, South Holland, Netherlands

Site Status

Szpital Uniwersytecki nr 2 im. dr. Jana Biziela /ID# 233321

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie /ID# 221667

Lublin, Lublin Voivodeship, Poland

Site Status

Lux Med Onkologia - Szpital Szamocka /Id# 222203

Warsaw, Masovian Voivodeship, Poland

Site Status

MTZ Clinical Research Powered by Pratia /ID# 221354

Warsaw, Masovian Voivodeship, Poland

Site Status

Uniwersyteckie Centrum Kliniczne /ID# 222069

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Pratia Onkologia Katowice /ID# 224728

Katowice, , Poland

Site Status

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopern /ID# 221784

Lodz, Łódź Voivodeship, Poland

Site Status

Pan American Center for Oncology Trials, LLC /ID# 221010

Rio Piedras, , Puerto Rico

Site Status

VA Caribbean Healthcare System /ID# 221012

San Juan, , Puerto Rico

Site Status

Kaluga Regional Clinical Hospital /ID# 221211

Kaluga, Kaluga Oblast, Russia

Site Status

Republican hospital named after V.A. Baranov /ID# 221214

Petrozavodsk, Murmansk Oblast, Russia

Site Status

Clinic UZI 4D /ID# 221215

Pyatigorsk, Stavropol Kray, Russia

Site Status

Hospital n.a. V.V. Veresaev /ID# 225435

Moscow, , Russia

Site Status

MMCC Kommunarka /ID# 221213

Moscow, , Russia

Site Status

Almazov National Medical Research Centre /ID# 221449

Saint Petersburg, , Russia

Site Status

Duplicate_Pusan National University Hospital /ID# 232353

Busan, Busan Gwang Yeogsi, South Korea

Site Status

Seoul National University Bundang Hospital /ID# 221695

Seongnam-si, Gyeonggido, South Korea

Site Status

Seoul National University Hospital /ID# 221226

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Asan Medical Center /ID# 221227

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Samsung Medical Center /ID# 221224

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Yonsei University Health System Severance Hospital /ID# 233171

Seoul, , South Korea

Site Status

Hospital Universitario Germans Trias i Pujol /ID# 221274

Badalona, Barcelona, Spain

Site Status

Hospital Universitario Reina Sofia /ID# 221273

Córdoba, Cordoba, Spain

Site Status

Hospital Universitario Quironsalud Madrid /ID# 221275

Pozuelo de Alarcón, Madrid, Spain

Site Status

Hospital Universitario Vall d'Hebron /ID# 221323

Barcelona, , Spain

Site Status

Hospital General Universitario Gregorio Maranon /ID# 221271

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre /ID# 221272

Madrid, , Spain

Site Status

Hospital Universitario de Salamanca /ID# 221297

Salamanca, , Spain

Site Status

Hospital Universitario Virgen del Rocio /ID# 221276

Seville, , Spain

Site Status

Hospital Universitario y Politecnico La Fe /ID# 221270

Valencia, , Spain

Site Status

Duplicate_Kaohsiung Chang Gung Memorial Hospital /ID# 223573

Kaohsiung City, Kaohsiung, Taiwan

Site Status

China Medical University Hospital /ID# 218987

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital /ID# 218989

Tainan City, , Taiwan

Site Status

Chi-Mei Medical Center /ID# 218991

Tainan City, , Taiwan

Site Status

Duplicate_Erciyes University Medical Fac /ID# 222090

Melikgazi, Kayseri, Turkey (Türkiye)

Site Status

Hacettepe University Faculty of Medicine /ID# 222094

Ankara, , Turkey (Türkiye)

Site Status

Ankara City Hospital /ID# 222093

Ankara, , Turkey (Türkiye)

Site Status

Akdeniz Universitesi Tip Fakul /ID# 222095

Antalya, , Turkey (Türkiye)

Site Status

Ondokuz mayis University Facul /ID# 222091

Samsun, , Turkey (Türkiye)

Site Status

Acibadem Maslak Hastanesi /ID# 222072

Tuzla, , Turkey (Türkiye)

Site Status

Derriford Hospital and the Royal Eye Infirmary /ID# 222514

Plymouth, Devon, United Kingdom

Site Status

University Hospitals Dorset NHS Foundation Trust /ID# 221237

Poole, Dorset, United Kingdom

Site Status

University College London Hospital /ID# 221240

London, Greater London, United Kingdom

Site Status

Oxford University Hospitals NHS Foundation Trust /ID# 221231

Oxford, Oxfordshire, United Kingdom

Site Status

Cardiff & Vale University Health Board /ID# 221236

Cardiff, Wales, United Kingdom

Site Status

NHS Grampian /ID# 222509

Aberdeen, , United Kingdom

Site Status

University Hospitals Birmingham NHS Foundation Trust /ID# 221233

Birmingham, , United Kingdom

Site Status

University Hospitals Bristol /ID# 222510

Bristol, , United Kingdom

Site Status

The Royal Marsden NHS Foundation Trust /ID# 221232

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Brazil Canada China Czechia France Germany Hungary Israel Italy Japan Netherlands Poland Puerto Rico Russia South Korea Spain Taiwan Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Stahl M, DeZern AE. Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Lancet Haematol. 2024 Jan;11(1):e5-e7. doi: 10.1016/S2352-3026(23)00343-5. Epub 2023 Dec 5. No abstract available.

Reference Type DERIVED
PMID: 38065202 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://www.rxabbvie.com

This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-507153-16-00

Identifier Type: OTHER

Identifier Source: secondary_id

M15-954

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

VA as Maintenance Therapy Post Allo-HSCT in MDS and AML
NCT06598384 NOT_YET_RECRUITING PHASE2